What is the role of intravenous immunoglobulin (IVIG) in the treatment of acute GVHD following allogeneic BMT?

Updated: Jul 05, 2018
  • Author: Jessica Katz, MD, PhD, FACP; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Answer

IVIG has been shown to decrease the severity of acute graft versus host disease in recipients of allogeneic bone marrow transplants. The dosage is 250 or 500 mg/kg/wk. Prevention against acute graft versus host disease with IVIG might be mediated by the induction of apoptosis of activated alloreactive CD4+ CD134+ donor T cells. [37]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!